Clorox (CLX) PT Lowered to $133.00

Clorox (NYSE:CLX) had its target price decreased by stock analysts at Morgan Stanley from $140.00 to $133.00 in a research report issued on Monday. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 4.72% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research raised Clorox from a “hold” rating to a “buy” rating and set a $163.00 price target on the stock in a report on Monday, January 8th. Jefferies Group reissued a “hold” rating and set a $132.00 price target on shares of Clorox in a report on Wednesday, November 1st. Royal Bank of Canada reissued a “hold” rating and set a $115.00 price target on shares of Clorox in a report on Sunday, October 8th. Wells Fargo & Co reissued a “hold” rating and set a $130.00 price target on shares of Clorox in a report on Wednesday, December 13th. Finally, Deutsche Bank initiated coverage on Clorox in a report on Wednesday, December 13th. They set a “hold” rating and a $142.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company’s stock. Clorox presently has a consensus rating of “Hold” and an average target price of $133.48.

Shares of Clorox (NYSE CLX) traded down $3.91 during trading on Monday, reaching $127.00. The company had a trading volume of 2,426,930 shares, compared to its average volume of 1,123,105. Clorox has a one year low of $123.58 and a one year high of $150.40. The company has a market cap of $16,640.00, a PE ratio of 21.26, a P/E/G ratio of 3.15 and a beta of 0.31. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.35.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Friday, February 2nd. The company reported $1.23 EPS for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.01. The business had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.43 billion. Clorox had a return on equity of 126.70% and a net margin of 13.21%. The business’s quarterly revenue was up .7% on a year-over-year basis. During the same period last year, the firm earned $1.14 earnings per share. equities research analysts anticipate that Clorox will post 6.2 EPS for the current fiscal year.

In other news, SVP Matthew T. Laszlo sold 20,051 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $130.46, for a total transaction of $2,615,853.46. Following the completion of the transaction, the senior vice president now owns 10,896 shares in the company, valued at $1,421,492.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Michael R. Costello sold 10,574 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $136.01, for a total value of $1,438,169.74. Following the transaction, the senior vice president now owns 34,867 shares of the company’s stock, valued at approximately $4,742,260.67. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

Several institutional investors have recently modified their holdings of CLX. FMR LLC grew its position in shares of Clorox by 0.8% during the second quarter. FMR LLC now owns 106,828 shares of the company’s stock valued at $14,234,000 after purchasing an additional 879 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Clorox by 7.2% during the second quarter. Dimensional Fund Advisors LP now owns 472,584 shares of the company’s stock valued at $62,967,000 after purchasing an additional 31,843 shares in the last quarter. Balyasny Asset Management LLC grew its position in shares of Clorox by 98.2% during the second quarter. Balyasny Asset Management LLC now owns 33,292 shares of the company’s stock valued at $4,436,000 after purchasing an additional 16,497 shares in the last quarter. AHL Partners LLP grew its position in shares of Clorox by 18.6% during the second quarter. AHL Partners LLP now owns 25,699 shares of the company’s stock valued at $3,424,000 after purchasing an additional 4,028 shares in the last quarter. Finally, Gotham Asset Management LLC purchased a new position in Clorox in the second quarter worth about $703,000. Hedge funds and other institutional investors own 73.68% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Clorox (CLX) PT Lowered to $133.00” was first published by American Banking and Market News and is the sole property of of American Banking and Market News. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/05/clorox-clx-pt-lowered-to-133-00.html.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.